Frank S. Walsh

Frank S. Walsh is the founder and CEO of Ossianix, a Biotechnology company that develops single domain VNAR antibodies for biologics drug delivery to the brain. Frank was previously head of Discovery Research worldwide at Wyeth Pharmaceuticals in Collegeville, PA (2002-2009). Prior to joining Wyeth, he was SVP at GlaxoSmithKline UK and Head of the Neurology CEDD since 2000. From 1997-2000 he was VP of Neuroscience Research at Smith Kline Beecham UK. Before joining the pharmaceutical industry, Frank had a distinguished academic career in Neuroscience as the Sir William Dunn Professor of Experimental Pathology at London’s UMDS, Guy’s Hospital and Institute of Neurology, Queen Square.

Frank received his Ph.D. from University College London and BSc from University of Strathclyde in Glasgow. His postdoctoral work was with Marshall Nirenberg at the NIH, Bethesda, USA. He has been awarded Honorary degrees from the Universities of Bologna and Perugia in Italy and Dundee and Strathclyde in Scotland. He is a fellow of the Royal Society of Edinburgh, the Academy of Medical Sciences in London, and King’s College London.